Table 1.

Treatment-emergent nausea and vomiting adverse events occurring during approximately 1 day following a single subcutaneous exenatide dose (10 μg) by MedDRA Preferred Term, intensity and anti-emetic treatment [population: ITT (n = 120)]

	Group by anti-emetic treatment
	Non-premedicated (n = 60)*			Premedicated (n = 60)*			All subjects (n = 120)*
Preferred term Intensity	n†	(%)	Events	n†	(%)	Events	n†	(%)	Events
Nausea	37	(61.7)	41	10	(16.7)	12	47	(39.2)	53
Mild	35	(58.3)	36	8	(13.3)	10	43	(35.8)	46
Moderate	5	(8.3)	5	2	(3.3)	2	7	(5.8)	7
Severe	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0
Vomiting	23	(38.3)	47	4	(6.7)	5	27	(22.5)	52
Mild	23	(38.3)	36	4	(6.7)	5	27	(22.5)	41
Moderate	2	(3.3)	11	0	(0.0)	0	2	(1.7)	11
Severe	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0

^*Number of ITT subjects in the corresponding group.

^†Number of subjects who experienced the adverse event.

Percentages are based on the number of ITT subjects in each group or in ‘All subjects’. Subjects experiencing multiple episodes of a given adverse event are counted once.

ITT, intent to treat; MedDRA®, Medical Dictionary for Regulatory Activities version 11.